Project managing a multidisciplinary pan-European programme focused on atrial fibrillation.
Pera Technology’s project management expertise is renowned as being a vital component behind the success of many large research programmes. Nowhere is this more true than with the EUTRAF project, aimed at improving care in patients with atrial fibrillation. Pera Technology is a key partner in this project offering a dedicated project management resource to all of the partners.
Throughout the duration of this €12m FP7 funded programme, our experienced Senior Project Managers managing every aspect of the project from start to finish, working closely with all partners to ensure they are meeting their technical deliverables and report deadlines for the EC. They also assist with dissemination activities of the project, arrange partner meetings where they all discuss the project, liaise with all partners and assist them with administration tasks.
Lasting five years, the EUTRAF (European Network for Translational Research in Atrial Fibrillation) project is a large scale collaborative project focussed on integrated research from organisations across Europe. It is focussed on exploring disease mechanisms and developing better diagnostic means and new therapies in patients with atrial fibrillation.
As project managers, Pera Technology is bringing together the expertise of a multidisciplinary consortium consisting of academic research groups and industry partners who are all actively involved in atrial fibrillation research.
Atrial fibrillation is the most common sustained cardiac rhythm disturbance, occurring in between 1 and 2% of the general population. It is estimated that over 10 million Europeans suffer from this arrhythmia and its prevalence is calculated to double in the next 50 years as the population ages.
At least one percent of the healthcare budget of Western European and North American countries is spent on the management of atrial fibrillation. Atrial fibrillation therefore presents a rapidly growing social, medical and public health problem.
With the ultimate mission of improving the management of atrial fibrillation in Europe, Pera Technology is central to the process of identifying patients who are at-risk for atrial fibrillation at an early stage, leading to better understanding of the factors that can lead to persistent atrial fibrillation.
Another important strategy which Pera Technology is overseeing is the development of accurate diagnostic tools that identify disease mechanisms in an individual patient, and the design of a specific therapy for each patient based on these individual factors.